Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression

Roy, Tina; An, J.; Doucette, Kimberly; Chappell, Aimee

doi:10.1080/10428194.2021.2010065

Cited by 8 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the published cases, nine patients had primary PCL, while four patients had secondary PCL ( 4 – 6 , 11 – 20 ). All patients harbored t(11;14) or BCL 2 overexpression; 3 patients had 17p deletion or TP53 mutation ( 6 , 11 , 19 ); and three cases had a complex karyotype ( 14 , 15 , 18 ). Venetoclax was given in combination in almost all cases except three patients ( 5 , 12 , 15 ) with a dose range of 100 mg to 1200 mg.…”

Section: Literature Review and Discussionmentioning

confidence: 99%

“…All patients harbored t(11;14) or BCL 2 overexpression; 3 patients had 17p deletion or TP53 mutation ( 6 , 11 , 19 ); and three cases had a complex karyotype ( 14 , 15 , 18 ). Venetoclax was given in combination in almost all cases except three patients ( 5 , 12 , 15 ) with a dose range of 100 mg to 1200 mg. In the case reported by Mikala et al., pharmacological enhancement was used to achieve an equivalent dose of 1200 mg daily while administering 400 mg of venetoclax through the concomitant use of a CYP3A4 inhibitor ( 20 ).…”

Section: Literature Review and Discussionmentioning

confidence: 99%

“…The majority of patients [n=6)] achieved sCR/CR ( 5 , 6 , 11 , 13 , 19 , 20 ), VGPR [n=4] ( 12 , 16 – 18 ) and PR [n=2] ( 15 ), while one patient with secondary PCL and complex karyotype was refractory to the venetoclax combination ( 14 ). The treatment was well tolerated in almost all treated patients; grade I thrombocytopenia was reported in three cases, and there was no reported tumor lysis syndrome.…”

Section: Literature Review and Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Venetoclax in the treatment of secondary plasma cell leukemia with translocation t(11;14): a case report and literature review

Elsabah,

Ghasoub,

El Omri

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

IntroductionVenetoclax is a BCL-2 inhibitor with proven efficacy in patients with multiple myeloma (MM) and translocation t(11;14). However, its role in plasma cell leukemia (PCL) remains unclear. Herein, we aimed to report a case of relapsed MM with secondary PCL and t(11;14) achieving complete (CR) and durable remission with venetoclax therapy.Case presentationA 52-year-old gentleman was diagnosed with MM-free light chain lambda (ISS III) in December 2016. He received induction therapy, followed by autologous stem cell transplant. (ASCT) in May 2017 and maintenance. A year later, the patient relapsed with secondary PCL. His cytogenetics analysis revealed t(11; 14). The patient failed salvage chemotherapy and was shifted to venetoclax with dexamethasone treatment. The patient attained complete remission (CR), which was maintained for two years and a half before he developed fatal COVID-19 pneumonia.ConclusionIn comparison with the reported literature, this case report offers the latest compilation of the available evidence on the use of venetoclax in patients with PCL. Furthermore, our patient achieved CR for the longest reported durable response in literature thus far. Prospective clinical trials are needed to elucidate the optimal dosage, combination, and duration of treatment, ensuring better representation and generalizability of the findings. Meanwhile, venetoclax may be considered as a therapeutic option in patients with PCL t(11;14).

show abstract